Related Experiment Video

Updated: Aug 16, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

766

Thyroid hormone Beta receptor agonists for treatment of kidney disease: A promising agent?

Sidar Copur1, Furkan Yavuz1, Mehmet Kanbay2

  • 1Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.

European Journal of Clinical Investigation
|December 20, 2022
PubMed
Abstract

Insights

Thyroid hormone beta receptor agonists show promise for managing chronic kidney disease (CKD). These drugs may help treat fatty kidney and nonalcoholic fatty liver disease, conditions often linked to CKD.

Area of Science:

  • Nephrology
  • Endocrinology
  • Hepatology

Background:

  • Chronic kidney disease (CKD) is a widespread condition with significant health impacts.
  • Obesity and hyperlipidemia are common in CKD patients, potentially leading to fatty kidney.
  • CKD and fatty kidney share pathophysiological links with nonalcoholic fatty liver disease (NAFLD).

Purpose of the Study:

  • To explore the potential therapeutic benefits of thyroid hormone beta receptor agonists in managing CKD.
  • To investigate the shared mechanisms between NAFLD and CKD that might be targeted by these agonists.

Main Methods:

  • This study is a narrative review.
  • It synthesizes existing research on thyroid hormone beta receptors, CKD, and NAFLD.

Main Results:

  • Thyroid hormone beta receptors are highly expressed in both liver and kidney tissues.
  • NAFLD and CKD exhibit numerous overlapping pathophysiological pathways and triggers.
  • Thyroid hormone beta receptor agonists have demonstrated positive outcomes in NAFLD patients.

Conclusions:

  • Given the shared mechanisms and receptor expression, thyroid hormone beta receptor agonists represent a potential therapeutic strategy for CKD.
  • These agonists may offer a novel approach to managing patients with CKD, potentially improving organ function and patient outcomes.
Keywords:
albuminuriachronic kidney diseasefatty kidneyinflammationnonalcoholic fatty liver diseasethyroid hormone beta receptors

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.2K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
482
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
680
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
503
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
229
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
736
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
67